Cathy Friedman
CIK: 0001411874
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
Director
Discretionary Trading P&L
Holdings
About FRIEDMAN CATHY
FRIEDMAN CATHY (SEC CIK 0001411874) files insider reports with the SEC as Director of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 2 ownership filings by FRIEDMAN CATHY, all Form 4s, filed between May 19, 2025 and Jun 12, 2026. Those filings report 2 transactions, from May 15, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FRIEDMAN CATHY's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by FRIEDMAN CATHY
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller